MYO MYOMO, INC.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1369290 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.3%
TTM net income YoY-25.4%
TTM EPS YoY-25.0%
Revenue 3-yr CAGR34.9%
Net income 3-yr CAGR—
Margins
Gross margin70.1%
Operating margin-21.8%
Net margin-33.1%
FCF margin-12.7%
EBITDA margin-18.8%
Returns
ROE-173.5%
ROA-44.4%
ROIC (approx.)-154.0%
Asset turnover1.34x
Leverage & solvency
Liabilities / assets91.9%
Debt / equity4.89x
Current ratio1.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.44x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue-1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.33M | $11.70M | $10.11M | $11.35M | $10.09M | $9.65M | $9.83M | $12.07M |
| Cost of revenue | $3.54M | $3.26M | $3.21M | $3.57M | $3.65M | $3.60M | $3.22M | $3.45M |
| Gross profit | $8.79M | $8.44M | $6.90M | $7.78M | $6.44M | $6.05M | $6.61M | $8.62M |
| R&D expense | $1.81M | $1.72M | $1.62M | $1.62M | $1.53M | $2.00M | $1.79M | $1.56M |
| SG&A expense | $3.58M | $3.71M | $3.62M | $3.43M | $3.18M | $3.41M | $3.94M | $3.60M |
| Operating income | -$1.72M | -$2.25M | -$3.16M | -$2.77M | -$3.52M | -$4.59M | -$3.52M | -$245,314 |
| Pretax income | -$4.13M | -$3.99M | -$2.82M | -$3.73M | -$3.53M | -$4.48M | -$3.33M | -$175,283 |
| Income tax | $103,874 | $31,404 | $186,715 | $83,878 | $135,658 | $148,201 | $136,795 | $84,798 |
| Net income | -$4.23M | -$4.02M | -$3.01M | -$3.81M | -$3.66M | -$4.63M | -$3.47M | -$260,081 |
| EBITDA | -$1.32M | -$1.87M | -$2.87M | -$2.51M | -$3.27M | -$4.40M | -$3.36M | -$153,750 |
| EPS (basic) | -0.10 | -0.09 | -0.07 | — | -0.09 | -0.11 | -0.08 | — |
| EPS (diluted) | -0.10 | -0.09 | -0.07 | — | -0.09 | -0.11 | -0.08 | — |
| Weighted avg. shares (diluted) | 43.57M | 42.70M | 42.27M | — | 42.17M | 41.58M | 41.45M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.10M | $11.22M | $11.40M | $14.13M | $12.55M | $14.24M | $19.79M | $24.37M |
| Short-term investments | $847,027 | $2.23M | $4.30M | $4.26M | $0 | $1.24M | $4.30M | $492,990 |
| Receivables | $5.92M | $4.95M | $4.82M | $4.10M | $5.29M | $7.05M | $4.66M | $3.83M |
| Inventory | $3.10M | $3.17M | $3.55M | $3.12M | $3.65M | $4.13M | $3.37M | $3.17M |
| Current assets | $23.50M | $24.53M | $25.66M | $27.56M | $22.95M | $28.04M | $31.10M | $32.79M |
| PP&E, net | $1.73M | $1.99M | $2.24M | $2.21M | $3.71M | $2.91M | $1.84M | $1.33M |
| Total assets | $33.80M | $35.34M | $36.75M | $38.64M | $34.08M | $38.67M | $40.87M | $42.24M |
| Current liabilities | $12.27M | $10.61M | $9.39M | $8.35M | $9.20M | $11.75M | $11.68M | $10.17M |
| Short-term debt | $1.79M | $446,962 | $2.73M | $0 | $583,333 | $166,667 | — | $2.95M |
| Long-term debt | $11.65M | $11.53M | $10.93M | $11.22M | $2.42M | $1.33M | — | $11.22M |
| Total debt | $13.44M | $11.98M | $13.66M | $11.22M | $3.00M | $1.50M | — | $14.18M |
| Total liabilities | $31.05M | $29.51M | $27.75M | $27.23M | $19.45M | $21.06M | $19.18M | $17.53M |
| Shareholders' equity | $2.75M | $5.83M | $9.00M | $11.40M | $14.63M | $17.62M | $21.69M | $24.71M |
| Net debt | $2.34M | $759,999 | $2.26M | -$2.91M | -$9.55M | -$12.74M | — | -$10.20M |
| Shares outstanding | 40.05M | 39.53M | 38.57M | 38.47M | 38.43M | 37.78M | 34.44M | 34.38M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.31M | -$1.94M | -$2.20M | -$1.14M | -$1.83M | -$8.87M | -$2.68M | $3.37M |
| Capital expenditure | $50,759 | $32,441 | $327,807 | -$1.24M | $1.05M | $1.26M | $670,688 | $860,248 |
| Free cash flow | -$1.36M | -$1.98M | -$2.53M | $98,146 | -$2.88M | -$10.12M | -$3.35M | $2.51M |
| Investing cash flow | $1.32M | $2.02M | -$494,345 | -$4.59M | $189,698 | -$757,348 | -$1.90M | -$1.35M |
| Financing cash flow | -$126,947 | -$243,709 | $0 | $7.51M | -$50,000 | $4.00M | -$36,506 | $15.77M |
| Depreciation & amortization | $405,656 | $384,539 | $291,590 | $263,263 | $246,851 | $190,798 | $158,442 | $91,564 |
| Stock-based compensation | $1.32M | $1.04M | $597,248 | $564,959 | $583,991 | $394,889 | $540,204 | $321,858 |
Free plan shows the latest 8 periods; Pro shows all 42 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.